COronary Native Artery First in Man Investigation of ISA 247 Elution to Prevent Restenotic Mechanisms.

Trial Profile

COronary Native Artery First in Man Investigation of ISA 247 Elution to Prevent Restenotic Mechanisms.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2013

At a glance

  • Drugs Voclosporin (Primary)
  • Indications Angina pectoris; Asymptomatic myocardial ischaemia; Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms CONFIRM-1
  • Sponsors Atrium Medical Corporation
  • Most Recent Events

    • 05 Apr 2011 Results presented at the 60th Annual Scientific Session of the American College of Cardiology.
    • 01 Oct 2010 Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 Scientific Symposium, according to an Isotechnika Pharma media release.
    • 22 Jan 2009 Status changed from recruiting to active, no longer recruiting as reported by Isotechnika.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top